

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): April 8, 2009**

---

**NABI BIOPHARMACEUTICALS**

(Exact Name of Registrant as specified in its charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-04829**  
(Commission File Number)

**59-1212264**  
(IRS Employer  
Identification No.)

**12276 Wilkins Avenue, Rockville, Maryland**  
(Address of principal executive offices)

**20852**  
(Zip Code)

**Registrant's telephone number, including area code: (301) 770-3099**

**Not Applicable**  
(Registrant's name or former address, if change since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On April 8, 2009, Leslie Hudson, Ph.D., notified the Chairman of the Board of Nabi Biopharmaceuticals (the "Company") that he would not seek re-election as a director of the Company at the Company's upcoming annual meeting of stockholders scheduled for May 22, 2009 but would serve out the remainder of his current term. Dr. Hudson currently is President, Chief Executive Officer and a director of AVI BioPharma, Inc., a biopharmaceutical company based in Portland, Oregon. Dr. Hudson's decision was personal and not based upon a difference of opinion with the Company or other members of the Board of Directors.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NABI BIOPHARMACEUTICALS

By: /s/ Raafat E.F. Fahim, Ph.D.  
Raafat E.F. Fahim, Ph.D.  
President and Chief Executive Officer

Date: April 14, 2009